Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM. Ceolin V, et al. Among authors: rubinstein jd. Leukemia. 2023 Jan;37(1):53-60. doi: 10.1038/s41375-022-01740-9. Epub 2022 Oct 30. Leukemia. 2023. PMID: 36310183
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
Rubinstein JD, Shah R, Breese EH, Burns KC, Mangino JL, Norris RE, Lee L, Mizukawa B, O'Brien MM, Phillips CL, Perentesis JP, Pommert L, Absalon MJ. Rubinstein JD, et al. Pediatr Blood Cancer. 2021 Aug;68(8):e29126. doi: 10.1002/pbc.29126. Epub 2021 May 21. Pediatr Blood Cancer. 2021. PMID: 34019326
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD, Breese EH, Krupski MC, O'Brien MM, Dandoy CE, Mizukawa B, Khoury R, Norris RE, Davies SM, Phillips CL. Rubinstein JD, et al. Transplant Cell Ther. 2023 May;29(5):311.e1-311.e7. doi: 10.1016/j.jtct.2023.02.012. Epub 2023 Feb 19. Transplant Cell Ther. 2023. PMID: 36809824 Free article.
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
LeBlanc FR, Breese EH, Burns KC, Chang EK, Jones LM, Lee L, Mizukawa B, Norris RE, O'Brien MM, Phillips CL, Perentesis JP, Rubinstein J, Pommert L. LeBlanc FR, et al. Br J Haematol. 2024 Sep;205(3):1055-1066. doi: 10.1111/bjh.19679. Epub 2024 Jul 31. Br J Haematol. 2024. PMID: 39082439
Acute myeloid leukemia in SRP54-mutated congenital neutropenia.
Sabulski A, Grier DD, Myers KC, Davies SM, Rubinstein JD. Sabulski A, et al. Among authors: rubinstein jd. EJHaem. 2022 Mar 16;3(2):521-525. doi: 10.1002/jha2.413. eCollection 2022 May. EJHaem. 2022. PMID: 35846055 Free PMC article.
37 results